Tag: KDC-MN-345

  • Etomidate

    GABA-A receptor positive allosteric modulator (intravenous anesthetic)

    An imidazole intravenous induction anesthetic; cardiovascular stable but causes adrenocortical suppression.

    Abstract

    Etomidate ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; CAS 33125-97-2; molecular formula C14H16N2O2; molecular weight 244.29) is an imidazole intravenous induction anesthetic developed at Janssen and approved by the FDA in 1972 (Amidate). The compound is a GABA-A receptor positive allosteric modulator with a binding site at the beta-2 and beta-3 subunits that produces preferential activity at extrasynaptic and synaptic GABA-A receptors. Distinct among IV anesthetics by minimal cardiovascular effects (preserved blood pressure and heart rate), making it preferred for patients with hemodynamic instability. The principal limitation is dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1), the final enzyme in cortisol biosynthesis; even a single induction dose suppresses cortisol for 4 to 6 hours, with potential clinical consequence in critically ill patients. Plasma half-life is approximately 2 to 5 hours. Used as a reference IV anesthetic with cardiovascular stability and adrenocortical suppression.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.